Table 1.

AML sample information

NumberAgeGenderWHO diagnosisCytogenetics% BlastsPrevious treatment
AML20480MaleAML without maturationNormal95Nil
AML20566FemaleTherapy-related myeloid neoplasmComplex851999 DAT, DAT MACE, MiDAC (50)
AML206a61MaleAML with myelodysplasia-related changesComplex80Nil
AML20753MaleAcute promyelocytic leukemia with t(15;17) (q22:q12) PML-RARAt(15;17)95bNil
AML20877MaleAML with myelodysplasia -related changesComplex95Nil
AML20949MaleAML with maturationNormal80Nil
AML21039MaleAML with maturationNormal65Nil
AML21158MaleAcute erythroid leukemiaNormal70Nil
AML21264MaleAML with t(8;21)(q22;q22);RUNX1-RUNX1T1t(8;21)85Nil
AML21392FemaleAML with myelodysplasia- related changesNot available70Nil
AML21657MaleAML with myelodysplasia- related changesNormal55Nil
AML21782FemaleAML with myelodysplasia -related changesDeletion 1385Hydroxycarbamide
AML30146FemaleAML with maturation+4, +8, t(9;22)70Nil
AML30340MaleAcute promyelocytic leukemia with t(15;17)(q22:q12) PML-RARAt(15;17)95b1999 DAT, DAT MACE, MiDAC (50)
AML30566FemaleAML without maturationt(2;12)65Nil
AML30678MaleAML with myelodysplasia- related changesNot available85Nil
AML30757MaleAML with minimal differentiationNot available952009 DA, DA, MACE, MiDAC (50)
  • NOTE: AML disease characteristics including WHO diagnosis and cytogenetics. Percentage blast denotes % of AML blasts after purification using density gradient and in some instances CD34+ positive selection (aisolated through CD34-positive selection. b% of blasts and promyelocytes). Previous treatments are as outlined (50).